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Cysteinyl leukotrienes (cysLTs), such as LTC4, LTD4, and LTE4, can
augment the accumulation of eosinophils in the tissues of asth-
matic airways. We previously reported that LTD4 up-regulates the
expression of b2 integrins on human eosinophils in vitro and in-
creases eosinophil adhesion.1 We also reported that LTD4 directly
induces transendothelial migration, superoxide anion generation,
and the degranulation of eosinophils.2 Administration of leuko-
triene receptor antagonist (LTRA) reduces the number of eosino-
phils in sputum of asthmatics, which supports the role of cysLTs
in the accumulation of eosinophils in airways. Moreover, recent ev-
idence suggests that cysLTs are increased in the airways during
virus-induced asthma.3 As the numbers of eosinophils and neutro-
phils increase in asthmatic airways during virus infection, cysLTs
may be involved in the virus-induced enhancement of eosinophilic
inﬂammation. Therefore, LTRA may provide a useful strategy for
controlling virus-induced eosinophilic airway inﬂammation and
asthma exacerbation.
Interferon-g-inducible protein of 10 kDa (IP-10) is involved in
the virus-induced exacerbation of asthma. For example, rhinovirus
(RV) infection induces bronchial epithelial cells to produce IP-10
in vitro and in vivo, and serum IP-10 concentrations are speciﬁcally
increased in RV-induced asthma exacerbation.4 The increased
levels of IP-10 correlate with disease severity during RV-induced
exacerbation. IP-10 binds to CXCR3 expressed on eosinophils. We
reported that IP-10 up-regulates eosinophil functions such as adhe-
sion, the generation of superoxide anion, degranulation, and cyto-
kine production.5 These ﬁndings suggest that IP-10 may also be
involved in the development of eosinophilic inﬂammation in
asthma during viral infection.
Intercellular adhesion molecule 1 (ICAM-1) is an adhesion
molecule that plays an important role in the recruitment of
inﬂammatory cells and is a cellular receptor for most RV-A and
all RV-B species of RV. Furthermore, RV infection increases
ICAM-1 expression on epithelial cells,6 and adhesion to ICAM-1
can activates eosinophil functions. In this study, to evaluate the
relevance of LTRA for virus-induced eosinophilic inﬂammation,
we examined whether montelukast, the most commonly
prescribed LTRA, modiﬁes the IP-10-induced eosinophil adhesion
to ICAM-1.
Eosinophils were isolated from the peripheral blood of non-
atopic healthy donors and by negative selection usingPeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).immunomagnetic beads as described previously.5,7 The study pro-
cedures were approved by the Ethics Committee of Saitama Medi-
cal University Hospital, and informed consent was obtained from
the donors before sample collection. Eosinophils (100 ml of medium
with 105 cells/ml) were pre-incubated with either montelukast or
control medium for 15 min. The eosinophils were then incubated
with LTD4 (100 nM) or IP-10 (100 nM) in ICAM-1-coated plates
for 20 min. Eosinophil adhesion to ICAM-1 was assessed based on
the residual eosinophil peroxidase (EPO) activity of adherent eosin-
ophils.5,7 For determination of cysLT production, eosinophils
(106 cells/ml) were incubated with or without IP-10 in the presence
of ICAM-1 for 180 min, and the cysLT concentrations in the super-
natant were measured by ELISA (Cayman). Results were compared
using a one-way factorial analysis of variance with Tukey's test for
multiple comparisons or a paired t-test for analysis of the differ-
ences between two groups.
Althoughmontelukast (1e10 mM) alone had no effect on sponta-
neous eosinophil adhesion (Fig. 1a), it suppressed LTD4 (100 nM)-
induced eosinophil adhesion to ICAM-1 (Fig. 1b); both of these re-
sults were consistent with previous reports.8 We then examined
the effect of LTRA on IP-10-induced eosinophil adhesion to ICAM-
1. As we previously reported,5 IP-10 (100 nM) enhanced the adhe-
siveness of eosinophils to ICAM-1 (Fig. 2a). Montelukast (1e10 mM)
signiﬁcantly suppressed IP-10-induced eosinophil adhesion to
ICAM-1 (Fig. 2a; IP-10 (100 nM) alone 21.6% ± 0.5%, montelukast
(1 mM) 14.3% ± 0.4%, P < 0.05, montelukast (10 mM) 11.1% ± 0.3%,
P < 0.01). Finally, we examined whether IP-10 up-regulates produc-
tion of cysLT from eosinophils. IP-10 induced cysLT production from
eosinophils in the presence of ICAM-1 (Fig. 2b; control
101.9 ± 9.9 pg/ml, IP-10 (100 nM) 171.1 ± 16.8 pg/ml, P < 0.05).
Similar results were obtained after 20-min incubation, although
their concentrations were much lower than those after 180-min in-
cubation (data not shown).
Recent evidence suggested that LTRA may be useful for the
treatment of virus-induced asthma exacerbation. Bisgaard et al. re-
ported that montelukast could suppress asthma symptoms of res-
piratory syncytial virus bronchiolitis.9 Furthermore, they also
reported that montelukast suppressed the frequency of virus-
induced asthma exacerbation.10 In this study, we found that mon-
telukast suppressed the eosinophil adhesion induced by the
virus-infection-related proteins IP-10 and ICAM-1 (Fig. 2a), sup-
porting the usefulness of LTRA treatment for virus-induced airway
inﬂammation and asthma exacerbation.
The mechanisms underlying the suppression of IP-10-induced
eosinophil adhesion by LTRA were not fully clariﬁed in this study.
We found that IP-10 induced cysLT production from eosinophilsvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Fig. 1. Effects of LTRA on spontaneous or LTD4-induced adhesion of eosinophils. (a) Effect of LTRA on spontaneous eosinophil adhesiveness to ICAM-1. Eosinophils (100 ml of medium
with 105 cells/ml) were incubated with or without montelukast (0.1 mM/1 mM/10 mM) at 37 C for 15 min. The adhesiveness of eosinophils to ICAM-1 was assessed using residual
EPO assays. Data are shown as means ± standard error of the mean (SEM) of eight experiments using cells from different donors. (b) Effect of LTRA on eosinophil adhesiveness to
ICAM-1 enhanced by LTD4. Eosinophils were pre-incubated with montelukast (0.1 mM/1 mM/10 mM) for 15 min, and then stimulated with LTD4 (100 nM). The adhesiveness of eo-
sinophils to ICAM-1 was assessed using residual EPO assays. Data are shown as means ± SEM of eight experiments using cells from different donors. **P < 0.01 vs. eosinophil adhe-
sion without LTD4 (control). #P < 0.05 and ##P < 0.01 vs. eosinophil adhesion enhanced by LTD4 without montelukast.
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Fig. 2. Effect of LTRA on IP-10-induced adhesion of eosinophils. (a) Effect of LTRA on eosinophil adhesiveness to ICAM-1 enhanced by IP-10. Eosinophils were pre-incubated with
montelukast (0.1 mM/1 mM/10 mM) for 15 min, and then stimulated with IP-10 (100 nM). The adhesiveness of the eosinophils to ICAM-1 was assessed using residual EPO assays. Data
are shown as means ± SEM of eight experiments using cells from different donors. **P < 0.01 vs. eosinophil adhesion without IP-10 (control). #P < 0.05 and ##P < 0.01 vs. eosinophil
adhesion enhanced by IP-10 without montelukast. (b) Effect of IP-10 on the production of cysLTs from eosinophils. Eosinophils (106 cells/ml) were incubated with or without IP-10
(100 nM) in the presence of ICAM-1 for 180 min. Then, the cysLT concentrations in the supernatant were measured by ELISA. *P < 0.05 vs. the control (without IP-10).
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phils may play roles in the increased eosinophil adhesion
induced by IP-10 in an autocrine fashion. In other words, IP-10-
induced eosinophil adhesion may be partly due to the actions
of the cysLTs produced by IP-10. We previously reported that
LTRA partially suppresses IL-5-induced eosinophil adhesion.8 As
IL-5 and ICAM-1 can up-regulate the generation of cysLTs by eo-
sinophils, we speculate that IL-5-induced eosinophil adhesion
may also be partly due to the actions of cysLTs produced by IL-
5. Taken together, if generation of cysLTs is induced, LTRA may
suppress eosinophil adhesion in a non-speciﬁc manner irrespec-
tive of stimulants.
One limitation in interpreting the ﬁndings of our study is that
there is little information on montelukast concentrations in plasma
or airways. After oral administration of 10 mg of montelukast, the
maximum plasma concentration of montelukast reaches approxi-
mately 865 nM (526 ng/ml) according to the Japanese drug package
insert; this value is almost the same as the concentration used in
this study. Therefore, it is possible to postulate that adhesion ofperipheral blood eosinophils to endothelium can be affected by
clinical use of montelukast.
In conclusion, LTRA suppressed eosinophil adhesion to ICAM-1
when eosinophils are stimulated with IP-10. As IP-10 and ICAM-1
are involved in virus infection and virus-induced asthma exacerba-
tion, our results suggest that administration of LTRA could be an
effective strategy for treating asthma exacerbation.Acknowledgements
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